Flucinar, 0.025% ointment 15 g

Flucinar is a synthetic GKS for external use. It has anti-inflammatory, antipruritic, anti-allergic, anti-exudative effects.

The mechanism of anti-inflammatory action is not fully understood. Fluocinolone acetonide inhibits the synthesis of prostaglandins and leukotrienes by inhibition of phospholipase A2 activity and reduces the release of arachidonic acid from phospholipids of the cell membrane. It prevents local allergic reactions in the skin. Antiexudative effect is caused by the vasoconstrictor action.

Pharmacokinetics

Easy penetration into the skin through the stratum corneum. Does not undergo biotransformation in the skin and cumulates in the stratum corneum. Fluociolone acetonide is detectable in the skin even after 15 days of topical application.

When used topically, fluocinolone acetonide may be slightly absorbed into the systemic bloodstream and cause general effects. The absorbed part is biotransformed mainly in the liver and is excreted from the body as compounds with glucuronic acid and in small amounts in unbound form. It is excreted mainly with urine and slightly with bile.

Absorption of fluocinolone acetonide is more pronounced when it is applied to the face and affected areas of the skin, as well as when using occlusive dressings. In addition, absorption of the drug increases when it is used frequently and when applied to large areas of skin. Absorption of the drug in children is more pronounced than in adults.

Indications

Acute and severe non-infectious, dry inflammatory skin diseases of various origins, accompanied by itching and hyperkeratosis, treatable with GCS:

Active ingredient

Composition

Active ingredient:

Fluocinolone acetonide 0.25 mg;

Associates:

Propylene glycol;

Citric acid;

Lanolin anhydrous;

Vaseline white.

How to take, the dosage

Externally. Apply to the affected surface, rubbing gently, 1-2 times a day, not more than 2 g/day. In psoriasis it is possible to use occlusive dressing. Course duration is not more than 1-2 weeks. On the skin of the face it is used very cautiously and not more than 1 week.

Children over 2 years of age – with caution, only once a day, on small areas of skin.

Special Instructions

Long-term use of Flucinard should be avoided. Prolonged use of GCS on large areas of the skin increases the frequency of adverse reactions in the form of peripheral edema, arterial hypertension, hyperglycemia, immunosuppressive effects.

If secondary infection develops at the site of application of Flucinar, antibacterial and antifungal therapy should be prescribed.

Particular caution should be exercised when using the drug on the skin of the eyelids or in the eye area in patients with glaucoma and with cataracts due to possible increase in the symptoms of the disease.

When the drug is applied to the skin of the face, its absorption increases and even after a short-term use the possibility of side effects (telangiectasia, skin atrophy, perioral dermatitis) increases. Extra caution should be exercised when using the drug in this area.

Persons with existing atrophic skin changes, especially elderly patients, should use Flucinard with caution.

Contraindications

Side effects

Skin and subcutaneous fatty tissue atrophy, lupus-like syndrome with a mild course, the appearance or exacerbation of symptoms of squamous capitis, disorders of epithelialization, delayed wound and ulcer healing, petechiae, steroid purpura, stretch marks, hirsutism, female pattern baldness, maculopapular skin rash.

Overdose

Symptoms: if the dosing regimen is not followed (prolonged use of the drug on large areas of skin) systemic side effects of the drug such as increased BP, edema, immunosuppressive effects are possible.

Treatment: discontinuation of the drug.

Similarities